Opendata, web and dolomites


A disruptive Magnetically Enhanced Library preparation platform for Next Generation Sequencing

Total Cost €


EC-Contrib. €






 MAGELIA project word cloud

Explore the words cloud of the MAGELIA project. It provides you a very rough idea of what is the project "MAGELIA" about.

scientists    cheaper    put    400    manual    leader    magelia    instrument    business    meet    fast    miniaturised    entirely    platform    trl6    tool    paris    1000    first    ngs    market    modern    won    democratise    breaking    advisory    pharmacy    times    board    renowned    secured    inception    biologists    initiate    ground    off    earlier    faster    biotech    companies    upstream    samples    backed    reagents    labs    2016    raw    prototype    confirmed    reproducibility    leverages    finish    engineers    billion    preparations    series    scarce    commercialization    clinicians    2021    curie    generation    spin    revolution    awards    genomics    customers    inorevia    miniaturized    platforms    biological    biology    company    volumes    medicine    tackle    larger    round    struggle    automated    seed    turnover    team    persons    preparation    ten    sme    smaller    trl8    grants    succeed    sequencing    patents    holds    15    accelerating    france    exclusive    rights    ignite    expensive    ready    medium    cnrs    throughput    accelerate    institut    talents    microfluidics    library   

Project "MAGELIA" data sheet

The following table provides information about the project.


Organization address
address: 6 RUE JEAN CALVIN
city: PARIS
postcode: 75005
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙000 €
 EC max contribution 1˙955˙100 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INOREVIA FR (PARIS) coordinator 1˙955˙100.00


 Project objective

Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform. After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market. To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round. The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGELIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGELIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HUD (2018)


Read More